Nephrologists with opinions (so, all of you): We’re recruiting for our recurring feature, “5 Nephrologists, 1 Question.” Short answers (~100 words), real-world concerns, no lectures. 📧 Email: charlotte[dot]robinson[at]formedics[dot]com #nephrology #nephsky

In a trial in Thailand, no significant differences in health-related quality of life were found between children with stage 5 CKD receiving automated vs continuous ambulatory peritoneal #dialysis. #nephrology #nephsky #PediatricNephrology www.docwirenews.com/post/automat...

In the ALCHEMIST trial, spironolactone did not reduce major #cardiovascular events in people with kidney failure receiving chronic #hemodialysis. #nephrology #nephsky www.docwirenews.com/post/study-d...

The SAFE-D pilot trial shows recruitment and adherence are feasible for anticoagulation strategies in people with AF receiving #dialysis. #nephrology #nephsky #AtrialFibrillation www.docwirenews.com/post/pilot-t...

Hot takes, but make them #nephrology. 🔥🩺 Looking for clinicians to contribute to a recurring feature: “5 Nephrologists, 1 Question.” Short answers. Rotating topics. More fun than polishing a manuscript. 📧 Email: charlotte[dot]robinson[at]formedics[dot]com #nephsky

In adults with provoked VTE and enduring risk factors, 12 months of low-dose apixaban reduced recurrent clots with a low risk of major bleeding. #nephrology #nephsky #dialysis www.docwirenews.com/post/apixaba...

In the RENIS cohort, higher physical activity was linked to slower GFR decline and lower risk of accelerated kidney function loss over 11 years. #nephrology #nephsky www.docwirenews.com/post/physica...

In a post hoc ADVOCATE analysis, avacopan improved kidney recovery, reduced relapse, and lowered glucocorticoid toxicity in people with GPA or MPA and kidney involvement. #nephrology #nephsky #granulomatosis #polyangiitis www.docwirenews.com/post/avacopa...

The phase 3 APPEAR-C3G study showed iptacopan significantly reduced proteinuria at 6 months in people with C3 glomerulopathy. #nephrology #nephsky #C3G www.docwirenews.com/post/iptacop...

In a national cohort from the Netherlands, 37% of children treated for cancer developed #AKI, which strongly predicted #CKD at 1 year. #nephrology #nephsky www.docwirenews.com/post/kidney-...

Have 10 minutes and an opinion about kidneys? 🫘 We’re seeking contributors for “5 Nephrologists, 1 Question.” One #nephrology question. Short answer. Email: charlotte[dot]robinson[at]formedics[dot]com #nephsky

We are delighted to announce that Anna Gaddy, MD, has joined the Nephrology Times editorial board. www.docwirenews.com/post/nephrol...

New Year’s resolutions tend to fail by February. Reading Nephrology Times is one you can actually keep. Happy New Year. 🥂 nephtimes.com

Research suggests a validated risk-prediction tool can estimate an individual patient’s likelihood of survival with conservative care compared with dialysis in advanced chronic kidney disease. Read more on Nephrology Times. 👉 www.docwirenews.com/post/predict... #nephrology #ckd #kidneydisease

Pediatric results from DUPLEX show sparsentan is well tolerated and achieves superior, sustained proteinuria reduction versus the maximum IRB dose in FSGS. #KidneyWk #nephsky #Nephrology #FSGS #Pediatrics www.docwirenews.com/post/sparsen...

Do you have strong opinions about #nephrology and ~10 minutes? 👀 Participate in our recurring feature: “5 Nephrologists, 1 Question.” Short (~100 words), practical, clinician-focused answers to a neph question. 📧 Email: charlotte[dot]robinson[at]formedics[dot]com #nephsky

What role do CD38+ immune cells play in AMR and glomerular disease? Georg Böhmig, MD, shares insights from #KidneyWk and what’s next for CD38-targeted therapies. #nephrology #nephsky #kidneytransplantation #kidneydisease www.docwirenews.com/post/targeti...

🩺 Nephrologists: Speak up! Want to share your insight in a future “5 Nephrologists, 1 Question” feature? Send an email to charlotte[dot]robinson[at]formedics[dot]com.

ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pMN. #KidneyWk #nephsky #Nephrology #ClinicalTrials www.docwirenews.com/post/povetac...

SPRINT data show intensive BP control favors most CKD patients, with greatest net benefit in those with lower eGFR. #KidneyWk #nephrology #CKD #hypertension #nephsky www.docwirenews.com/post/intensi...

🩺 Nephrologists: Speak up! Want to share your insight in a future “5 Nephrologists, 1 Question” feature? Send an email to charlotte[dot]robinson[at]formedics[dot]com.

ICYMI: 12-month VISIONARY results show sibeprenlimab sustains proteinuria reduction and remission in IgA nephropathy. #KidneyWk #nephrology #IgAN #kidneydisease #nephsky www.docwirenews.com/post/protein...

What should clinicians know about ADTKD? A recent review details disease subtypes, genetic testing, and practical management considerations. #nephrology #ADTKD #nephsky #kidneydisease www.docwirenews.com/post/review-...

We spoke with Stefano Stuard, MD, PhD, about the clinical advantages of #hemodiafiltration and its slow adoption in the US. #nephrology #dialysis #nephsky www.docwirenews.com/post/hemodia...

John Gill, MD, spoke with us about the latest data on tegoprubart vs. tacrolimus for immunosuppression in kidney transplantation. #nephsky #nephrology #kidneytransplantation #immunosuppression www.docwirenews.com/post/promisi...

In his column, Dr. Ajay Singh highlights the role of AI augmentation in electron microscopy of the kidneys. #nephrology #nephsky #electronmicroscopy #ai #artificialintelligence www.docwirenews.com/post/ai-and-...

ICYMI: Joel Topf @kidneyboy.bsky.social spoke with Vesna Garovic of Mayo Clinic at #KidneyWk about pregnancy and hypertension, the topic of Dr. Garovic's inaugural Sharon Silbiger, MD, Endowed Lecture. #nephsky #nephrology #hyptertension #pregnancy www.docwirenews.com/post/hyperte...

Don't miss our Kidney Week coverage, including research news and interviews with researchers and presenters. #nephrology #kidneywk #nephsky www.docwirenews.com/conference/a...

📖 🛋️ It's the weekend! Catch up on our latest issue, featuring the state of neph training, glom trial design, Kidney Week, and more. #nephrology #kidneydisease #nephsky www.docwirenews.com/journal/dece...

Mike Spigler of @kidneyfund.bsky.social spoke with us about a study on housing instability and food insecurity among people with ESKD. #nephsky #kidneydisease #sdoh #foodinsecurity #housinginstability www.docwirenews.com/post/housing...

WATCH Matthew Weir, MD, discussing results from the phase 2 Explore-CKD trial of lorundrostat presented at #KidneyWk. #nephrology #nephsky #kidneydisease #CKD #hypertension www.docwirenews.com/post/lorundr...

Drs. Ben Talbot and Claudio Hegenberger of Emerald Clinical discuss cardio-kidney-metabolic syndrome, screening and risk detection, and management. #nephrology #nephsky #ckm #ckmsyndrome www.docwirenews.com/post/stemmin...

Question for #NephSky: How do you decide when to initiate dialysis in a patient with borderline indications? Leave a comment with your answer, and we may feature it in our next "5 Nephrologists, 1 Question" column. #nephrology

With a growing need for kidney care and declining interest in nephrology, how are training programs evolving to bolster the future workforce? #fellowship #nephrology #nephsky #medicaltraining www.docwirenews.com/post/the-sta...

Question for #NephSky: How do you decide when to initiate dialysis in a patient with borderline indications? Leave a comment with your answer, and we may feature it in our next "5 Nephrologists, 1 Question" column. #nephrology

📩 Are you on our email list? If not, sign up today to get nephrology news and views delivered straight to your inbox. www.docwirenews.com/page/subscribe

Dr. Carla Nester discussed 52-week data on pegcetacoplan for #C3G demonstrating sustained proteinuria reduction (and remission in a third of patients). #nephrology #nephsky #glomerulardisease #kidneywk www.docwirenews.com/post/52-week...

We caught up with Richard Lafayette after #KidneyWk to discuss ORIGIN-3 results presented at the meeting showing strong proteinuria reduction with ataciceipt in #IgAnephropathy. #nephsky #nephrology #igan www.docwirenews.com/post/atacice...

All of our #KidneyWk interviews from Houston are now available on our website. But there is even more coverage to come! We caught up with several presenters to discuss their research after the meeting. Find all our coverage here. 👉 www.docwirenews.com/conference/a... #nephrology #nephsky

The December issue of Nephrology Times is online NOW, featuring the state of nephrology fellowship, AI in electron microscopy, glomerular trial design, and much more. Read here ➡️ www.docwirenews.com/journal/dece... #nephrology #nephsky

Drs. Joel Topf and Brad Rovin spoke at #KidneyWk about the latest on belimumab and lupus nephritis therapies. #nephrology #lupusnephritis #nephsky @kidneyboy.bsky.social www.docwirenews.com/post/lupus-n...

Happy Thanksgiving to our US readers. (pikisuperstar / Freepik)

👓 WATCH NOW: Richard Knight, MD, talks about ongoing challenges in kidney transplantation and how emerging tools and strategic policies might help. #kidneytransplant #transplantation #nephrology #nephsky www.docwirenews.com/post/the-kid...

👀 WATCH NOW: Joel Topf @kidneyboy.bsky.social caught up with Rajiv Agarwal at #KidneyWk in Houston, where the latter presented CONFIDENCE findings on implementation of finerenone and empagliflozin. #nephrology #nephsky #kidneydisease #hyperkalemia #sglt2 www.docwirenews.com/post/hyperka...

Another #KidneyWk, another showcase for #IgAN therapies. Joel Topf @kidneyboy.bsky.social spoke with Jonathan Barratt about his trials of mezagitamab and atacicept. #nephsky #nephrology #iganephropathy www.docwirenews.com/post/mezagit...

Check out 5 of our favorite highlights from ASN #KidneyWk. #nephrology #nephsky www.docwirenews.com/post/5-highl...

Joel Topf @kidneyboy.bsky.social spoke with Jai Radhakrishnan at #KidneyWk about his late-breaking research poster describing a new analysis of data from the DUPLEX trial of sparsentan in #FSGS. #nephsky #nephrology www.docwirenews.com/post/sparsen...

At #KidneyWk, we spoke with Hiddo J. L. Heerspink about the FINE-ONE trial and the first meaningful progress in T1D kidney disease in decades. #nephrology #nephsky #diabetes #kidneydisease www.docwirenews.com/post/trials-...

Our #KidneyWk coverage continues to roll out. Next up is our interview with Vlado Perkovic on the possibility of curing #kidneydisease and his take on the FINE-ONE and ORIGIN-3 trials presented on day 1 of the meeting. #nephrology #nephsky www.docwirenews.com/post/curing-...

ICYMI: KidneyCure, the philanthropic arm of ASN, will invest up to $6M in grants over 3 years to support kidney research. #kidneydisease #research #nephrology www.docwirenews.com/post/kidneyc...